Gennex Laboratories Limited (BOM:531739)

Market Cap	2.89B
Revenue (ttm)	1.49B
Net Income (ttm)	185.52M
Shares Out	227.45M
EPS (ttm)	0.78
PE Ratio	16.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	413,079
Average Volume	635,921
Open	12.91
Previous Close	13.03
Day's Range	12.50 - 13.19
52-Week Range	10.84 - 17.25
Beta	0.46
RSI	39.63
Earnings Date	Feb 13, 2026

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531739

Financial Performance

In 2024, Gennex Laboratories's revenue was 1.38 billion, an increase of 59.03% compared to the previous year's 867.14 million. Earnings were 181.23 million, an increase of 37.55%.